Nexalin Inks 10-Year Exclusive Distribution Deal for South America, Targets First Commercial Revenue
NXL sits 68% above its 52-week low of $4.
Summary
Nexalin signed a definitive 10-year exclusive distribution and local manufacturing agreement with Inovanexa Medical Technologies for Brazil and six other South American countries, covering over 300 million people. The deal includes a binding initial order for five devices, five more within 12 months of pilot, a 30-month ANVISA transition, and royalty-bearing local manufacturing required after 30 devices, funded entirely by the distributor. This marks Nexalin's first concrete path to commercial revenue after years of pre-revenue R&D, and follows its recent Nasdaq continued listing approval and reverse split. The agreement is capital-light for Nexalin, which retains IP and supplies encrypted boards, but revenue depends on distributor performance and regulatory transfers. Watch for the clinical pilot launch targeted within 90 days and the distributor's establishment of local manufacturing after purchasing 30 devices.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — The 8-K details the agreement: initial binding order for five devices, five more within 12 months of pilot, 30-month ANVISA transition, and local manufacturing required after 30 devices.
At the time of this announcement, NXL was trading at $6.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5M. The 52-week trading range was $4.00 to $60.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.